- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02552420
The Clinical Application of Infrared Thermal Imaging Detecting Venous Thromboembolism
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Willing to participate in the trial and sign the informed consent form,
- Aged: 18-75 years. They had been definitively diagnosed with venous thromboembolism,
- The bed-rest immobilization time should be more than 72 hours,
- Planing to gynecology operation,
- The D dimer should be more than500 g • L-1,
- There is no obvious symptoms of systemic infection two weeks before the test,
- There is no trauma, infection, biopsy or puncture, hemorrhage and tumor in the corresponding detection site (chest and lower limbs),
- There is no skin disease, heart, liver, kidney, gastrointestinal tract, hematopoietic system and mental, neurological has no serious diseases.
Exclusion Criteria:
- Patients can not be good partners,
- Doctors believe that there is any inappropriate situations.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Using the Infrared Thermal Imaging to detecting Venous Thromboembolism
Time Frame: up to 24 months
|
① Different levels of pseudocode (white, red, pink, yellow, green, blue, black) representing related IRTI that corresponds to a color scale bar of low to high temperatures, so we can know disease's position, extent and severity by comparing with the difference of color distribution and shape in the thermal imaging. ②The intensity of thermal distribution is higher than normals (great than or equal 0.5 Celsius degree is unnoraml), the symmetry of thermal range is relatively increased (pixels over 0.5 ~ 1.0-fold), the difference of spatial distribution of the thermal field and the difference of statistically analyze are related to the disease. |
up to 24 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GIRD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Deep Venous Thrombosis
-
Hospital de Clinicas de Porto AlegreCompletedDeep Venous Thromboses | Deep Venous Thrombosis of Left Leg | Deep Venous Thrombosis of Right Leg | Deep Venous Thrombosis Proximal
-
Intermountain Health Care, Inc.TerminatedDeep Vein Thrombosis | Venous Thromboembolism | Deep Venous Thrombosis | Thrombus | Upper Extremity Deep Venous ThrombosisUnited States
-
Tong ZhuNot yet recruitingDeep Vein Thrombosis | Deep Venous Insufficiency
-
Maastricht University Medical CenterTerminatedRandomized Clinical Trial | Deep-Venous Thrombosis | Deep Venous StentingNetherlands
-
Memorial Sloan Kettering Cancer CenterRecruitingVenous Thromboembolism | Deep Venous ThrombosisUnited States, Australia
-
Al-Nahrain UniversityNot yet recruitingDVT - Deep Vein Thrombosis | VTE (Venous Thromboembolism)Iraq
-
Imperial College LondonWithdrawnDeep Vein Thrombosis | Deep Venous Thrombosis of LegUnited Kingdom
-
University of Massachusetts, AmherstCompletedDeep Venous Thrombosis of Deep Femoral VeinUnited States
-
Milton S. Hershey Medical CenterEnrolling by invitation
-
Ottawa Hospital Research InstituteUniversity of Alberta; Hamilton Health Sciences Corporation; Queen Elizabeth...CompletedThromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines (TRIM-Line)Cancer | Central Venous Catheter Thrombosis | Upper Extremity Deep Vein ThrombosisCanada